Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Non-Small-Cell Lung 35Stomach Neoplasms 34Lung Neoplasms 13Neoplasms 12Adenocarcinoma 11Neoplasm Metastasis 10Colorectal Neoplasms 9Esophageal Neoplasms 7Carcinoma, Hepatocellular 7Colonic Neoplasms 5Carcinoma, Renal Cell 5Breast Neoplasms 5Adenocarcinoma Of Esophagus 5Urinary Bladder Neoplasms 3Urethral Neoplasms 3Rectal Neoplasms 3Melanoma 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Biliary Tract Neoplasms 3Ureteral Neoplasms 2Thymoma 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Metastatic Gastric Adenocarcinoma 2

Interventions

Fluorouracil 67Radiotherapy 53Cisplatin 52Oxaliplatin 47Leucovorin 37Paclitaxel 36Irinotecan 27Docetaxel 23Capecitabine 20Nivolumab 16Carboplatin 16pembrolizumab 15Radiation 15Neoadjuvant Therapy 15Surgical Procedures, Operative 12Cetuximab 12durvalumab 9Taxes 8Folfox protocol 8Drug Therapy 8Chemotherapy, Adjuvant 8Trastuzumab 7Magnetic Resonance Spectroscopy 7Gefitinib 7tremelimumab 6Endoscopy, Digestive System 6Endoscopy 6Biopsy 6Specimen Handling 5Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma Of Esophagus × Ramucirumab × Clear all
NCT06203600 2026-05-26

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT06251973 2026-05-15

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
20 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT04499924 2025-01-22

MOUNTAINEER-02

Seagen Inc.

Phase 2/3 Completed
17 enrolled 23 charts
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT03995017 2023-02-01

RiME

University of Kansas Medical Center

Phase 1/2 Unknown
34 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡